Clinical trials: Olanzapine
Bipolar Disorder
3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159744
- Testing
- Asenapine, Olanzapine
- Volunteers
- 488 people
- Sponsor
- Organon and Co
Depression
Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
OBJECTIVES: To evaluate the comparative efficacy and security of Continuation Electroconvulsive Therapy associated with pharmacotherapy versus pharmacotherapy alone in the prevention of depressive relapse.
- Trial name
- NCT01305707
- Testing
- C-ECT, PHARMACOTHERAPY
- Where
- 3 sites in Spain
- Volunteers
- 104 people
- Sponsor
- Hospital Universitari de Bellvitge
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Mood Disorders,
Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana
The purpose of this study is to evaluate a bundled intervention of psychotropic drugs and daily contact with a nurse for people with mental health disorders in a prayer camp and secondly to assess whether the attitudes of the…
- Conditions
- Schizophrenia, Mood Disorders,, Anxiety Disorder
- Trial name
- JFR (NCT02593734)
- Testing
- olanzapine, risperidone, amitryptaline
- Where
- Ghana
- Volunteers
- 139 people
- Sponsor
- University of Ghana Medical School
Schizophrenia
Exploratory Cognition Study of Sertindole in Patients With Schizophrenia
The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on neurocognitive functioning in patients with schizophrenia.
- Trial name
- NCT00759421
- Testing
- Sertindole, Olanzapine
- Where
- Taiwan
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Weight Gain
Effects of Modafinil on Olanzapine Weight Gain
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively.
- Trial name
- NCT00636896
- Testing
- Olanzapine plus modafinil
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Psychosis Nos/Other
Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis
The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed…
- Trial name
- NONSTOP (NCT01765829)
- Testing
- Discontinuation antipsychotic treatment, Antipsychotic treatment
- Where
- 17 sites in Spain
- Volunteers
- 104 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Treatment-resistant Schizophrenia
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
The specific aim of this protocol is to compare Clozapine treatment vs Non-Clozapine antipsychotic treatment in a population of treatment-refractory individuals with schizophrenia.
- Trial name
- NCT05741502
- Testing
- Clozapine, Antipsychotics,Other (non-Clozapine)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Schizophrenia, Schizoaffective Disorder
Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
The study involves a six-month, double-blind protocol during which eighty patients, across three sites around the country, will be randomly assigned to receive clozapine or olanzapine.
- Trial name
- NCT00179231
- Testing
- olanzapine vs. clozapine
- Volunteers
- 80 people
- Sponsor
- Vanderbilt University
Bipolar Disorder
Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
Background: Bipolar disorder is one of the most common mental illnesses affecting 1%-4% of the population, and one of the leading causes of worldwide disability.
- Trial name
- NCT01893229
- Testing
- Lithium, Valproate, Oxcarbazepine
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Guiyun Xu
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of…
- Trial name
- NCT00174265
- Testing
- asenapine, olanzapine
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
The purposes of this study are to determine: The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients…
- Trial name
- NCT00090012
- Testing
- Olanzapine, Quetiapine
- Where
- 25 sites in United States
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Weight Gain
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weight gain .
- Trial name
- NCT00191828
- Testing
- olanzapine
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Schizophrenic Disorders, Schizoaffective Disorder
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
- Trial name
- NCT00088465
- Testing
- Intramuscular olanzapine depot
- Where
- 92 sites in United States, Argentina and 23 more
- Volunteers
- 931 people
- Sponsor
- Eli Lilly and Company
Chemotherapy-induced Nausea and Vomiting
Anti-emetic Prophylaxis With or Without Dexamethasone
To evaluate the efficacy and safety of a fosaprepitant, tropisetron, and olanzapine antiemetic regimen, with or without dexamethasone, in patients receiving highly emetogenic chemotherapy with epirubicin and cyclophosphamide.
- Trial name
- NCT05242874
- Testing
- Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
- Where
- 2 sites in China
- Volunteers
- 442 people
- Sponsor
- Henan Cancer Hospital
Emotional Distress
Mechanism of Mindfulness Based Online Intervention in Reducing Emotional Distress
This study hopes to: 1. explore whether, at the individual level, the improvement of mindfulness ability can promote peace of mind, reduce the frequency of mental wandering, weaken or cut off the cycle between negative mood and…
- Trial name
- NCT05600790
- Testing
- Mindfulness Intervention for Emotional Distress
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00145496
- Testing
- Asenapine, Olanzapine
- Volunteers
- 468 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or…
- Trial name
- NCT00100776
- Testing
- Olanzapine
- Where
- 33 sites in United States
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company